Hikma Pharmaceuticals PLC (LON:HIK)
1,738.00
-39.00 (-2.19%)
Sep 2, 2025, 7:14 PM BST
Hikma Pharmaceuticals Revenue
Hikma Pharmaceuticals had revenue of $1.66B USD in the half year ending June 30, 2025, with 16.19% growth. This brings the company's revenue in the last twelve months to $3.22B, up 6.60% year-over-year. In the year 2024, Hikma Pharmaceuticals had annual revenue of $3.13B with 8.77% growth.
Revenue (ttm)
$3.22B
Revenue Growth
+6.60%
P/S Ratio
1.64
Revenue / Employee
$338.53K
Employees
9,500
Market Cap
3.85B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.13B | 252.00M | 8.77% |
Dec 31, 2023 | 2.88B | 358.00M | 14.22% |
Dec 31, 2022 | 2.52B | -36.00M | -1.41% |
Dec 31, 2021 | 2.55B | 212.00M | 9.06% |
Dec 31, 2020 | 2.34B | 134.00M | 6.07% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
HUTCHMED (China) | 439.54M |
Oxford Nanopore Technologies | 183.19M |
Genus | 671.60M |
Hikma Pharmaceuticals News
- 25 days ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Pre Recorded Earnings Call Transcript - Seeking Alpha
- 25 days ago - Hikma Pharmaceuticals PLC 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 25 days ago - Hikma Pharmaceuticals PLC (HKMPF) Q2 2025 Q&A Earnings Call Transcript - Seeking Alpha
- 26 days ago - Hikma Pharmaceuticals tumbles after injectables margin outlook cut - Reuters
- 5 weeks ago - Hikma Pharmaceuticals: a quality compounder waiting for a catalyst - The Armchair Trader
- 2 months ago - Hikma receives FDA approval for TYZAVAN™ (Vancomycin Injection, USP) in the US - PRNewsWire
- 2 months ago - Hikma Pharmaceuticals to invest $1B by 2030 to expand US manufacturing, R&D - Seeking Alpha
- 2 months ago - Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines - PRNewsWire